{
  "fullName": "Tasuku Honjo",
  "slug": "tasuku-honjo",
  "title": "MD",
  "specialty": "PD-1 Immunotherapy",
  "geography": {
    "country": "Japan",
    "region": null,
    "city": null
  },
  "status": "LIVING",
  "tier": "TITAN",
  "rankingScore": 28,
  "hIndex": 175,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "Tasuku Honjo  is a Japanese physician-scientist and immunologist. He won the 2018 Nobel Prize in Physiology or Medicine and is best known for his identification of programmed cell death protein 1 (PD-1). He is also known for his molecular identification of cytokines IL-4 and IL-5, as well as the discovery of activation-induced cytidine deaminase (AID) that is essential for class switch recombination and somatic hypermutation.",
  "aiSummary": "Tasuku Honjo is a pd-1 immunotherapy specialist with an H-index of 175 at Kyoto University (Faculty). Has been published in Cell, Proceedings of the National Academy of Sciences, Nature Immunology. Based in Japan.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Kyoto University"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Kyoto University",
      "role": "Faculty",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "PD-1 Immunotherapy"
  ],
  "knowsAbout": [
    "Nobel Prize in Physiology or Medicine"
  ],
  "citations": [
    {
      "title": "Spermidine activates mitochondrial trifunctional protein and improves antitumor immunity in mice.",
      "journal": "Science",
      "year": 2022,
      "citationCount": 0,
      "doi": "10.1126/science.abj3510",
      "pubmedId": "36302005",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/36302005/"
    },
    {
      "title": "B cell-derived GABA elicits IL-10(+) macrophages toÂ limit anti-tumour immunity.",
      "journal": "Nature",
      "year": 2021,
      "citationCount": 0,
      "doi": "10.1038/s41586-021-04082-1",
      "pubmedId": "34732892",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/34732892/"
    },
    {
      "title": "Anti-PD-1 antibodies recognizing the membrane-proximal region are PD-1 agonists that can down-regulate inflammatory diseases.",
      "journal": "Sci Immunol",
      "year": 2023,
      "citationCount": 0,
      "doi": "10.1126/sciimmunol.add4947",
      "pubmedId": "36638191",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/36638191/"
    },
    {
      "title": "Spermidine - an old molecule with a new age-defying immune function.",
      "journal": "Trends Cell Biol",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1016/j.tcb.2023.08.002",
      "pubmedId": "37723019",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/37723019/"
    },
    {
      "title": "Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling.",
      "journal": "Immunity",
      "year": 2024,
      "citationCount": 0,
      "doi": "10.1016/j.immuni.2024.10.014",
      "pubmedId": "39603236",
      "verified": true,
      "sourceUrl": "https://pubmed.ncbi.nlm.nih.gov/39603236/"
    }
  ],
  "awards": [],
  "timeline": [],
  "subSpecialty": null,
  "lastFixedAt": "2026-02-16T05:45:15.000Z",
  "portraitUrl": "https://upload.wikimedia.org/wikipedia/commons/thumb/b/b3/Tasuku_Honjo_201311.jpg/330px-Tasuku_Honjo_201311.jpg",
  "openalexId": "https://openalex.org/A5019039647",
  "bio": "## Dr. Tasuku Honjo: A Biography\n\nDr. Tasuku Honjo is a name synonymous with a paradigm shift in cancer treatment. While details of his current private practice remain largely undisclosed, his profound contributions to immunology, specifically his discovery of Programmed cell death protein 1 (PD-1) and its subsequent application in cancer immunotherapy, have cemented his place as a giant in the field of medicine. This biography aims to explore the trajectory of Dr. Honjo's career, from his early academic pursuits to his groundbreaking research and its lasting impact on the lives of countless patients.\n\n## 1. Early Life and Education\n\nBorn in Kyoto, Japan, Dr. Honjo's early life instilled in him a deep curiosity and a relentless pursuit of knowledge. His academic journey began with a strong foundation in science. He excelled in his studies, demonstrating a particular aptitude for understanding complex biological systems. This intellectual curiosity led him to the Faculty of Medicine at Kyoto University, one of Japan's most prestigious institutions.\n\nHis medical education at Kyoto University was rigorous, exposing him to the diverse facets of clinical practice and biomedical research. While the clinical aspects of medicine were undoubtedly valuable, it was in the realm of research that Dr. Honjo found his true calling. He was drawn to the intricacies of the immune system, recognizing its potential to be harnessed for the treatment of disease.\n\nAfter obtaining his M.D. in 1966, Dr. Honjo embarked on a path that would define his career: a focus on fundamental research. He pursued postgraduate studies in the United States, initially at the Carnegie Institution of Washington's Department of Embryology in Baltimore, Maryland. This experience broadened his scientific perspective and exposed him to cutting-edge research techniques. He then moved to the National Institutes of Health (NIH) in Bethesda, Maryland, where he continued his research in molecular biology. These formative years in the US, working alongside leading scientists, instilled in him a deep understanding of the scientific method and the importance of meticulous experimentation.\n\nUpon returning to Japan, Dr. Honjo held faculty positions at the University of Tokyo and Osaka University, further solidifying his academic credentials. These roles allowed him to establish his own research laboratory and begin exploring his burgeoning interest in the molecular mechanisms governing immune responses. It was during this period that he began to lay the groundwork for his groundbreaking discovery of PD-1. His early work focused on immunoglobulin gene rearrangement and class switching, providing crucial insights into the diversity and adaptability of the antibody response. This foundational research proved essential for understanding the complexities of the immune system, a critical prerequisite for his later work on PD-1.\n\n## 2. Medical Philosophy\n\nWhile primarily a researcher, Dr. Honjo's work is deeply intertwined with a profound understanding of patient care. His medical philosophy is rooted in the belief that fundamental scientific discoveries can be translated into tangible benefits for patients suffering from debilitating diseases. He approached his research with a keen awareness of the unmet clinical needs in oncology, driven by the desire to find more effective and less toxic treatments for cancer.\n\nDr. Honjo's innovative thinking is characterized by his willingness to challenge conventional wisdom and pursue unconventional research avenues. He was not afraid to question established paradigms and explore alternative hypotheses, a trait that ultimately led him to the discovery of PD-1. He possessed a remarkable ability to connect seemingly disparate pieces of information and formulate novel insights into the complex interplay between the immune system and cancer.\n\nHis practice ethics, though primarily reflected in his research, are undoubtedly grounded in the principles of scientific integrity and the responsible application of scientific knowledge. He is a strong advocate for rigorous research standards and the ethical conduct of clinical trials, ensuring that new treatments are developed and implemented in a safe and effective manner. His commitment to scientific rigor is evident in the meticulousness of his research and the thoroughness of his publications. He emphasizes the importance of reproducibility and validation in scientific research, ensuring that findings are robust and reliable.\n\nFurthermore, Dr. Honjo's approach emphasizes collaboration and interdisciplinary research. He recognized that complex biological problems require the expertise of multiple disciplines, fostering collaborations with clinicians, immunologists, molecular biologists, and other specialists. This collaborative approach allowed him to leverage the strengths of different disciplines to accelerate the pace of discovery and translate research findings into clinical applications.\n\n## 3. Key Procedures & Clinical Expertise\n\nAlthough Dr. Honjo's primary focus has been research, his work has had a profound impact on clinical practice, particularly in the field of PD-1 immunotherapy. While he may not directly perform surgical or other invasive procedures, his discovery of PD-1 has revolutionized the treatment of various cancers, leading to the development of PD-1 inhibitors, a class of drugs that have shown remarkable efficacy in patients with previously untreatable malignancies.\n\nHis expertise lies in the fundamental understanding of the PD-1 pathway and its role in regulating immune responses. He elucidated the molecular mechanisms by which PD-1 inhibits T cell activation, providing a crucial insight into how cancer cells evade immune surveillance. This knowledge paved the way for the development of PD-1 inhibitors, which block the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the immune system to attack cancer cells.\n\nWhile he isn't actively involved in private practice currently, his contributions have empowered oncologists to utilize PD-1 inhibitors effectively. This includes understanding patient selection criteria, managing immune-related adverse events, and optimizing treatment regimens. The clinical application of PD-1 inhibitors requires a deep understanding of immunology, pharmacology, and oncology, and Dr. Honjo's work has provided the scientific foundation for these clinical practices.\n\nThe impact of PD-1 immunotherapy extends to a wide range of cancers, including melanoma, lung cancer, kidney cancer, bladder cancer, and Hodgkin lymphoma. In many cases, PD-1 inhibitors have demonstrated durable responses and improved survival rates in patients who have failed to respond to conventional therapies. This has transformed the treatment landscape for these cancers, offering hope to patients who previously had limited treatment options.\n\n## 4. Academic Contributions & Research\n\nDr. Honjo's academic contributions are extensive and impactful. His research has been published in numerous high-impact journals, including *Nature*, *Science*, and *Cell*. His key publications have detailed the discovery of PD-1, its structure, function, and role in immune regulation. These publications have been cited thousands of times, highlighting the importance of his work to the scientific community.\n\nHis research focus areas include:\n\n*   **PD-1 and its Role in Immune Regulation:** Unraveling the molecular mechanisms by which PD-1 inhibits T cell activation and its implications for cancer immunotherapy.\n*   **Immunoglobulin Gene Rearrangement and Class Switching:** Elucidating the processes that generate antibody diversity and their role in adaptive immunity.\n*   **Activation-Induced Cytidine Deaminase (AID):** Discovering and characterizing AID, an enzyme essential for antibody diversification and somatic hypermutation.\n*   **Molecular Mechanisms of Immune Tolerance:** Understanding how the immune system distinguishes between self and non-self and prevents autoimmune reactions.\n\nHis impact on medical science is undeniable. The discovery of PD-1 has not only revolutionized cancer treatment but has also provided valuable insights into the fundamental principles of immunology. His work has inspired countless researchers to explore the potential of immunotherapy for treating a wide range of diseases, including autoimmune disorders and infectious diseases. He has mentored numerous graduate students and postdoctoral fellows, shaping the next generation of immunologists and cancer researchers.\n\nDr. Honjo's research has also led to the development of novel biomarkers for predicting response to PD-1 immunotherapy. These biomarkers can help clinicians identify patients who are most likely to benefit from PD-1 inhibitors, allowing for more personalized and effective treatment strategies.\n\n## 5. Patient Impact & Community Work\n\nWhile Dr. Honjo's direct patient interaction details are not widely available, the impact of his discovery on patient outcomes is immeasurable. PD-1 immunotherapy has provided a lifeline to countless individuals suffering from advanced cancers, offering them the hope of remission, prolonged survival, and improved quality of life. The stories of patients who have benefited from PD-1 inhibitors are a testament to the transformative power of his research.\n\nHis contributions extend beyond the realm of clinical medicine. He is a strong advocate for scientific literacy and public awareness of scientific advancements. He has actively engaged in outreach activities, communicating the importance of scientific research to the general public. He has also been a vocal supporter of government funding for scientific research, recognizing the crucial role that research plays in advancing human health and well-being.\n\nDr. Honjo's commitment to community work is also reflected in his involvement in various scientific organizations and advisory boards. He has served on numerous committees and panels, providing his expertise and guidance to shape research policies and priorities. He has also been a mentor and advisor to young scientists, helping them to develop their research careers and contribute to the advancement of medical science.\n\nThe development of PD-1 inhibitors has had a significant economic impact as well, creating new jobs in the pharmaceutical industry and driving innovation in drug development. Dr. Honjo's work has not only improved human health but has also contributed to economic growth and prosperity.\n\n## 6. Legacy and Future Outlook\n\nDr. Tasuku Honjo's legacy is firmly established as a pioneer in cancer immunotherapy. He is widely regarded as one of the most influential immunologists of our time. His discovery of PD-1 has transformed the treatment of cancer and has opened up new avenues for exploring the potential of immunotherapy for treating a wide range of diseases.\n\nHis work has earned him numerous prestigious awards and honors, including the Tang Prize in Biopharmaceutical Science in 2014, the Kyoto Prize in Basic Sciences in 2016, and the Nobel Prize in Physiology or Medicine in 2018, which he shared with James P. Allison. These accolades are a testament to the significance of his contributions to medical science.\n\nLooking to the future, Dr. Honjo's work continues to inspire researchers to explore new strategies for harnessing the power of the immune system to fight cancer. Ongoing research is focused on developing novel PD-1 inhibitors, identifying biomarkers for predicting response to immunotherapy, and combining PD-1 inhibitors with other therapies to enhance their efficacy.\n\nHis lasting influence extends beyond the realm of cancer immunotherapy. His work has provided valuable insights into the fundamental principles of immunology, paving the way for the development of new treatments for autoimmune disorders, infectious diseases, and other immune-related conditions. He has left an indelible mark on the scientific community and has inspired countless researchers to pursue their passion for discovery and innovation. Dr. Honjo's legacy will continue to shape the future of medicine for generations to come. His unwavering commitment to scientific rigor, his innovative thinking, and his dedication to improving human health have made him a true giant in the field of medicine.\n",
  "bioGenerated": true
}